The Economics of Real-World Evidence: Why Legacy EDC Costs 10x What It Should

Executive Summary

The cost of generating real-world evidence is dominated not by technology licensing but by the human labor required to compensate for technology limitations. This whitepaper examines the true total cost of ownership for outcomes research infrastructure, identifies the primary cost drivers, and demonstrates how purpose-built platforms can reduce per-study costs by 80-90% through infrastructure reuse, automated data harmonization, and continuous quality management.

The Hidden Cost Structure

When research organizations evaluate their data infrastructure costs, they typically focus on direct technology expenses: software licenses, hosting, and vendor support. These visible costs represent approximately 15-20% of the true cost of generating real-world evidence.

The remaining 80-85% is labor — data management, quality assurance, custom integrations, and the opportunity cost of slow study timelines. Understanding this cost structure is essential for making informed infrastructure investment decisions.

Direct Technology Costs

The average legacy EDC deployment for an outcomes research study carries annual costs in the range of $50,000-$150,000 for software licensing and hosting. These costs are well-understood and budgeted for.

Data Management Labor

For every dollar spent on EDC licensing, research organizations spend $3-5 on data management labor. This includes:

• Data extraction and cleaning — Manual or semi-automated processes to extract data from source systems (EHRs, labs, registries) and prepare it for analysis. Typical cost: 2-3 FTEs per active study.
• Data harmonization — Mapping data from disparate sources into a common analytical format. This is often the most labor-intensive step, particularly for multi-site studies with heterogeneous EHR systems.
• Quality management — Identifying and resolving data quality issues, which in legacy systems is typically a retrospective process that adds 3-6 months to study timelines.
• Custom reporting — Building study-specific reports and analytical datasets, which rarely benefit from prior work due to the one-off nature of legacy EDC configurations.

Timeline Costs

The most significant hidden cost is time. Legacy approaches to RWE generation typically require 12-24 months from study initiation to final dataset, with data management and quality activities accounting for 60-80% of that timeline.

This extended timeline has concrete economic consequences: delayed evidence generation, missed regulatory windows, and research questions that go unanswered because the projected timeline makes them infeasible.

The Infrastructure Reuse Multiplier

The fundamental economic insight is that most data management work in outcomes research is repetitive across studies. The same EHR systems, the same data quality issues, the same harmonization challenges appear study after study.

Legacy EDC treats each study as a standalone project. Purpose-built infrastructure treats each study as an incremental consumer of shared capabilities.

First-Study vs. Nth-Study Economics

With legacy infrastructure, Study 1 and Study 10 cost approximately the same in data management labor. Each study requires its own data extraction, harmonization, and quality processes.

With shared infrastructure, Study 1 is more expensive — it includes the cost of building data pipelines, harmonization rules, and quality frameworks. But Study 2 reuses 60-70% of that investment. By Study 5, marginal data management costs have declined by 80%.

This is the infrastructure reuse multiplier, and it’s the primary economic driver for purpose-built RWE platforms.

Quantifying the Difference

For a typical multi-site outcomes research program running 5-10 studies over 3 years:

Legacy EDC approach:

• Per-study data management cost: $200K-$500K
• Total program cost (10 studies): $2M-$5M
• Average time to final dataset: 18 months

Purpose-built infrastructure:

• First-study investment (includes infrastructure): $300K-$600K
• Marginal per-study cost (studies 2-10): $30K-$75K
• Total program cost (10 studies): $570K-$1.3M
• Average time to final dataset: 3-6 months

The crossover point — where purpose-built infrastructure becomes less expensive than legacy EDC on a cumulative basis — typically occurs between the second and third study.

Continuous Quality vs. Retrospective Quality

Legacy quality management is retrospective: data is collected, then cleaned, then validated. Issues discovered during validation frequently require returning to source data — sometimes months after collection.

Continuous quality management monitors data quality metrics in real-time, flagging issues at the point of ingestion. This approach reduces quality-related costs through:

• Earlier detection — Issues caught at ingestion cost 1/10th to resolve compared to issues caught during analysis.
• Source correction — Real-time feedback to contributing sites allows them to correct issues in their workflows, preventing recurrence.
• Reduced rework — Fewer late-stage data quality surprises mean fewer analytical do-overs.

Recommendations

Research organizations considering RWE infrastructure investments should:

1. Audit total cost of ownership, not just technology licensing. Include data management labor, timeline costs, and opportunity costs.
2. Evaluate infrastructure reuse potential. If your research portfolio includes more than 2-3 studies using similar data sources, shared infrastructure will be more economical than study-by-study EDC.
3. Prioritize continuous quality over retrospective quality. The cost savings from early detection compound over time.
4. Invest in data pipelines, not data projects. Reusable infrastructure is more expensive upfront but dramatically less expensive at scale.
5. Build on standards, not bespoke schemas. Ingesting via FHIR, harmonizing to the OMOP Common Data Model, and producing SDTM/CDASH outputs for submission lets each study reuse the prior study’s mapping work instead of starting over. Standards are where the reuse multiplier actually lives.

About This Analysis

This whitepaper is based on Principia Health Sciences’ experience building research infrastructure for disease associations, academic medical centers, and industry sponsors. Cost estimates are derived from our engagements and published benchmarks from CDISC, OHDSI, and Duke-Margolis Center for Health Policy. Contact us for a detailed cost analysis specific to your research portfolio.